Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XI...( ...),Health

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced several scientific presentations at the International Society on Thrombosis and Haemostasis (ISTH) XII Congress in Boston that will feature its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor antagonist currently in Phase II clinical development, and its oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, as well as a presentation by Portola co-founder David Phillips on new directions in antithrombotic drug discovery.

In the past six months, Portola has announced global development and commercialization agreements with Novartis for elinogrel and with Merck & Co., Inc. for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical development.

Scientific Presentations

A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor (Presentation #PP-MO-045)

    Presenter:   Helena Haberstock-Debic
    Date: Monday, July 13, 12:30-2:15 p.m.       
    Location:  Poster Area, Platelet Biology

New Directions in Antithrombotic Drug Discovery: Pharmacological Uncoupling of Arterial thrombosis from Hemostasis (Presentation #AS-TU-026)

    Presenter: David Phillips
    Date: Tuesday, July 14, 1:15-1:45 p.m.
    Location:  Room 104 ABC, Platelets and Systemic Disorders

The Antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128) in Patients with High Platelet Reactivity During Clopidogrel Therapy (Presentation #PP-WE-801)

    Presenter: Paul Gurbel
    Date: Wednesday, July 15, 12:30-2:15 p.m.   
    Location:  Poster Area, Patient Oriented Studies 
'/>"/>
SOURCE  Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 
Related medicine news :

1. Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
2. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
3. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
4. MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration
5. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
6. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
7. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
8. Arena Pharmaceuticals Announces Public Offering of Common Stock
9. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
10. Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
11. Jazz Pharmaceuticals Completes $7 Million Private Placement